| ID | 10040 |
| Vaccine Name | EpiVacCorona |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Approved |
| Manufacturer | FBRI State Research Center of Virology and Biotechnology |
| Year of Manufacturing | 2021 |
| Manufacturing Country | Russia |
| Age | 18 - 60 years |
| Dosage | 2 doses 21 or 28 days apart |
| Administration Route | Intramuscular |
| Adjuvant | Aluminum (aluminium hydroxide) |
| Target Strain | SARS-CoV-2 protein |
| Description | NA |
| Approving Organisation | Russian Federation |
| Collaborating Organisation | FBRI State Research Center of Virology and Biotechnology |
| Other Countries | Cambodia, Russia, Turkmenistan |
| Trade Name | EpiVacCorona-N, Aurora-CoV |
| PMID | 33402220 |
| Clinical Trial ID | NCT04780035 |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ |
| Additional Links | https://clinicaltrials.gov/ct2/show/NCT04780035
|